W. Lloyd Clark, MD

Clark describes visual and anatomic improvements with aflibercept 8 mg in the PULSAR extension study, with most patients achieving extended dosing regimens.

Key opinion leaders emphasize important considerations when discussing the safety of anti-VEGF agents with patients and highlight unmet needs in nonproliferative diabetic retinopathy treatments.

Drs Ehsan Rahimy and Joseph M. Coney analyze the implications of clinical trial data on the management of nonproliferative diabetic retinopathy.

A panel of experts reviews data on nonproliferative diabetic retinopathy treatments from the PANORAMA, Protocol W, RISE, and RIDE studies.

Dr Joseph M. Coney provides insight into the goals of therapy for patients with nonproliferative diabetic retinopathy.

Joseph M. Coney, MD, and Ehsan Rahimy, MD, explain the complications of nonproliferative diabetic retinopathy and emphasize the importance of early detection.

Drs Ehsan Rahimy and Diana V. Do define diabetic retinopathy and describe the symptoms.

Expert ophthalmologists debate the rationale behind choosing an anti-VEGF inhibitor for patients and the challenges involved in treatment management.

Key opinion leaders review the efficacy and safety of available VEGF inhibitors for the treatment of macular edema and explain how effectiveness is evaluated.

Experts in retinal diseases provide insight into when to prescribe VEGF inhibitors and the initial conversations with patients about treatment.

W. Lloyd Clark, MD, and Diana V. Do, MD, discuss their goals of treatment and the standard of care for macular edema.

Ehsan Rahimy, MD, and Diana V. Do, MD, explain the role of VEGF inhibitors in treating macular edema.